China Medical System Holdings Limited

867 KYG211081248

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 23/05/2024 pm IST			5-day change	1st Jan Change
6.77 ^HKD	-0.15%		-5.31%	-51.08%

09/05	China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
23/04	China Medical System's Anti-Anaemia NDA Accepted in China	MT

China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023

May 09, 2024 at 06:31 pm IST

China Medical System Holdings Limited at its Annual General Meeting Held on 9 May 2024 approved the recommended final dividend of RMB 0.0783 (equivalent to HKD 0.086) per share for the year ended 31 December 2023.

Latest news about China Medical System Holdings Limited

China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	09/05	CI
China Medical System's Anti-Anaemia NDA Accepted in China	23/04	MT
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	23/04	CI
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	23/04	MT
China Medical System Registers New Vitiligo Drug in Macau	17/04	MT
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.	02/04	CI
Incyte, China Medical System Sign Collaboration, License Agreement	01/04	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	01/04	CI
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024	27/03	CI
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial	20/03	MT
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China	19/03	CI
China Medical System Obtains Nod For Trials of Two Drugs	08/02	MT
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed	07/02	CI
China Medical Gains License to Sell Kidney Disease Drug Across China	05/02	MT
China Approves Phase 3 Clinical Trial for CMS' Vitiligo Cream	13/12	MT
China Includes CMS' Four Drugs in National Reimbursement List	13/12	MT
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China	12/12	CI
Chinese Regulator Approves China Medical System's Drug Appilcation for Methotrexate Injection	05/12	MT
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China	04/12	CI
Hangzhou HealSun Biopharm Co., Ltd. announced that it has received CNY 200 million in funding from Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited	07/23/07	CI
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	29/23/29	CI
China Medical System, A&B Revise Royalty Caps for Nasal Spray	13/23/13	MT
China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023	28/23/28	CI
China Medical System Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI

Chart China Medical System Holdings Limited

Duration

Period

Chart China Medical System Holdings Limited

More charts

Company Profile

China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Medical System Holdings Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.288 CNY

Average target price

10.08 CNY

Spread / Average Target

+60.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA MEDICAL SYSTEM HOLDINGS LIMITED	-51.08%	2.12B
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+34.74%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+16.51%	244B
NOVARTIS AG	+9.61%	208B
ROCHE HOLDING AG	-4.62%	205B
AMGEN INC.	+7.43%	166B

Other Pharmaceuticals